For cagrilintide, the question stops early
There was no approved cagrilintide or CagriSema product to cover as of September 2026.
For an approved alternative, four facts matter
- The exact brand and form.
- The reason it is being prescribed.
- The plan’s list of covered medicines.
- Any approval steps the plan requires before it pays.
Semaglutide products do not all have the same approved uses. Ozempic is tied to type 2 diabetes uses, while Wegovy has approved weight-management uses.
Questions for the plan
- Is this exact product on the plan list?
- Is it covered for the reason on the prescription?
- What records must the prescriber send?
- How much would I have to pay?
- Is there an appeal path if the answer is no?
Chapter recap
Start with product, reason, and plan. For cagrilintide, there is no approved product to put through that process yet.